Cancer survivorship - Genetic susceptibility and second primary cancers: Research strategies and recommendations Journal Article
| Authors: | Travis, L. B.; Rabkin, C. S.; Brown, L. M.; Allan, J. M.; Alter, B. P.; Ambrosone, C. B.; Begg, C. B.; Caporaso, N.; Chanock, S.; DeMichele, A.; Figg, W. D.; Gospodarowicz, M. K.; Hall, E. J.; Hisada, M.; Inskip, P.; Kleinerman, R.; Little, J. B.; Malkin, D.; Ng, A. K.; Offit, K.; Pui, C. H.; Robison, L. L.; Rothman, N.; Shields, P. G.; Strong, L.; Taniguchi, T.; Tucker, M. A.; Greene, M. H. |
| Article Title: | Cancer survivorship - Genetic susceptibility and second primary cancers: Research strategies and recommendations |
| Abstract: | Cancer survivors constitute 3.5% of the United States population, but second primary malignancies among this high-risk group now account for 16% of all cancer incidence. Although few data currently exist regarding the molecular mechanisms for second primary cancers and other late outcomes after cancer treatment, the careful measurement and documentation of potentially carcinogenic treatments (chemotherapy and radiotherapy) provide a unique platform for in vivo research on gene-environment interactions in human carcinogenesis. We review research priorities identified during a National Cancer Institute (NCI)-sponsored workshop entitled "Cancer Survivorship - Genetic Susceptibility and Second Primary Cancers." These priorities include 1) development of a national research infrastructure for studies of cancer survivorship; 2) creation of a coordinated system for biospecimen collection; 3) development of new technology, bioinformatics, and biomarkers; 4) design of new epidemiologic methods; and 5) development of evidence-based clinical practice guidelines. Many of the infrastructure resources and design strategies that would facilitate research in this area also provide a foundation for the study of other important nonneoplastic late effects of treatment and psychosocial concerns among cancer survivors. These research areas warrant high priority to promote NCI's goal of eliminating pain and suffering related to cancer. © The Author 2006. Published by Oxford University Press. All rights reserved. |
| Keywords: | cancer chemotherapy; cancer survival; cancer surgery; case-control studies; nonhuman; antineoplastic agents; note; united states; cancer radiotherapy; cancer incidence; neoplasms; biological marker; genetic predisposition to disease; cohort studies; radiotherapy; evidence based practice; cancer pain; practice guideline; radiation injury; biotechnology; cancer research; cancer survivor; survivors; carcinogenesis; drug hypersensitivity; registries; specimen handling; syndrome; neoplasms, radiation-induced; genetic susceptibility; mitomycin c; neoplasms, second primary; bioinformatics; clinical trials; drug induced disease; epidermal growth factor receptor kinase inhibitor; sampling; carcinogens; process development; documentation; workshop; multicenter studies; medical informatics; congresses; social psychiatry |
| Journal Title: | JNCI: Journal of the National Cancer Institute |
| Volume: | 98 |
| Issue: | 1 |
| ISSN: | 0027-8874 |
| Publisher: | Oxford University Press |
| Date Published: | 2006-01-01 |
| Start Page: | 15 |
| End Page: | 25 |
| Language: | English |
| DOI: | 10.1093/jnci/djj001 |
| PUBMED: | 16391368 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 79" - "Export Date: 4 June 2012" - "CODEN: JNCIA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work